Global Checkpoint Inhibitor Market to Achieve Double-Digit Growth

Expansion driven by agents in clinical trials targeting novel pathways

WELLESLEY, Mass, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Immune checkpoint inhibitors are causing a stir among oncologists, as they have proven to be effective in the treatment of many cancers. A new BCC Research study projects that the global market for checkpoint inhibitors will reach $29.3 billion in 2023 and examines it by drug target, region and indication.

Checkpoint inhibitors enhance the immune response to detect and target cancer cells, with a lower incidence of side effects compared with conventional chemotherapy. In addition, they provide durable responses that last for many years. From an estimated $14.9 billion in 2018, a five-year compound annual growth rate of 14.4% is projected, according to a new report by BCC Research Checkpoint Inhibitors: Global Markets.

In the last 5 years, acquisitions, equity offerings and venture capital have accounted for more than $3.3 billion invested in checkpoint inhibitors; another $1.3 billion has been spent to establish strategic partnerships for the development of checkpoint inhibitors.

Research Highlights

  • Upward of 230 clinical trials are underway, evaluating checkpoint inhibitors either as monotherapy or in combination with chemotherapy or targeted therapies.
  • Several agents that target novel pathways are in early-stage clinical development, including TIM-3, LAG-3, CD-47/SIRPα and IDO-1 inhibitors.
  • Precision medicine will be a major driver for pharma to effectively deliver these innovative medicines and ensure that they are accessible and available at sustainable prices to all of those who are in need.

“Many agents that modulate the immune system are beginning to emerge and change treatment paradigms,” said Dr. Cheryl Lee Barton, BCC Research analyst and author of this report. “Companies will discover clinically effective combinations and validate biomarker signatures that will help identify patients who are most likely to benefit from treatment.”

PD-1/PD-L1, CTLA-4 Are Most Prominent Targets

Checkpoint inhibitor revenues will increase as marketed therapies gain regulatory approval in new indications and territories. Immune checkpoint inhibitors targeting either the PD-1/PD-L1 or CTLA-4 pathway are the most promising. The US FDA has approved six checkpoint inhibitors for cancer, including two PD-1 inhibitors, three PD-L1 inhibitors, and one CTLA-4 inhibitor.

About BCC Research
BCC Research is a publisher of market research reports that provide organizations with intelligence to drive smart business decisions. By partnering with industry experts worldwide, BCC Research provides unbiased measurements and assessments of global markets covering major industrial and technology sectors, including emerging markets. For more information about BCC Research, please visit Follow BCC Research on Twitter at @BCCResearch.


Contact Data